Axcella Health Inc (NASDAQ:AXLA) was the target of a significant increase in short interest in March. As of March 13th, there was short interest totalling 113,100 shares, an increase of 17.9% from the February 27th total of 95,900 shares. Currently, 1.4% of the company’s shares are short sold. Based on an average daily trading volume, of 34,800 shares, the days-to-cover ratio is presently 3.3 days.
In other news, Director David R. Epstein purchased 12,800 shares of the stock in a transaction dated Thursday, February 27th. The stock was acquired at an average cost of $3.65 per share, for a total transaction of $46,720.00. Following the completion of the acquisition, the director now directly owns 66,098 shares in the company, valued at approximately $241,257.70. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Over the last quarter, insiders have bought 17,465 shares of company stock valued at $69,689.
A number of hedge funds have recently made changes to their positions in the business. State Street Corp acquired a new position in Axcella Health during the fourth quarter valued at approximately $230,000. Geode Capital Management LLC acquired a new position in Axcella Health during the fourth quarter valued at approximately $155,000. Bank of New York Mellon Corp acquired a new position in Axcella Health during the fourth quarter valued at approximately $80,000. UBS Group AG lifted its position in Axcella Health by 1,168.2% during the fourth quarter. UBS Group AG now owns 19,073 shares of the company’s stock valued at $76,000 after buying an additional 17,569 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. acquired a new position in Axcella Health during the fourth quarter valued at approximately $69,000. 63.27% of the stock is currently owned by hedge funds and other institutional investors.
Axcella Health (NASDAQ:AXLA) last released its earnings results on Monday, March 23rd. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.64) by ($0.04). As a group, sell-side analysts expect that Axcella Health will post -1.23 earnings per share for the current fiscal year.
Separately, Zacks Investment Research upgraded shares of Axcella Health from a “hold” rating to a “buy” rating and set a $3.00 price target for the company in a report on Tuesday, March 24th. Five research analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and a consensus price target of $17.25.
Axcella Health Company Profile
There is no company description available for Axcella Health Inc
Recommended Story: Equal Weight Rating
Receive News & Ratings for Axcella Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axcella Health and related companies with MarketBeat.com's FREE daily email newsletter.